JP2008521783A5 - - Google Patents

Download PDF

Info

Publication number
JP2008521783A5
JP2008521783A5 JP2007542113A JP2007542113A JP2008521783A5 JP 2008521783 A5 JP2008521783 A5 JP 2008521783A5 JP 2007542113 A JP2007542113 A JP 2007542113A JP 2007542113 A JP2007542113 A JP 2007542113A JP 2008521783 A5 JP2008521783 A5 JP 2008521783A5
Authority
JP
Japan
Prior art keywords
antibody
tnfα
fragment
antibody according
signaling via
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
JP2007542113A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008521783A (ja
Filing date
Publication date
Priority claimed from GBGB0425972.7A external-priority patent/GB0425972D0/en
Application filed filed Critical
Publication of JP2008521783A publication Critical patent/JP2008521783A/ja
Publication of JP2008521783A5 publication Critical patent/JP2008521783A5/ja
Abandoned legal-status Critical Current

Links

JP2007542113A 2004-11-25 2005-11-24 p55Rを介するTNFαシグナル伝達を選択的に抑制する抗TNFα抗体 Abandoned JP2008521783A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0425972.7A GB0425972D0 (en) 2004-11-25 2004-11-25 Biological products
PCT/GB2005/004511 WO2006056779A2 (en) 2004-11-25 2005-11-24 ANTI-TNF ALPHA ANTIBODIES WHICH SELECTIVELY INHIBIT TNF ALPHA SIGNALLING THROUGH THE p55R

Publications (2)

Publication Number Publication Date
JP2008521783A JP2008521783A (ja) 2008-06-26
JP2008521783A5 true JP2008521783A5 (enExample) 2009-01-08

Family

ID=33561379

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007542113A Abandoned JP2008521783A (ja) 2004-11-25 2005-11-24 p55Rを介するTNFαシグナル伝達を選択的に抑制する抗TNFα抗体

Country Status (6)

Country Link
US (1) US9840556B2 (enExample)
EP (1) EP1817344B9 (enExample)
JP (1) JP2008521783A (enExample)
ES (1) ES2553129T3 (enExample)
GB (1) GB0425972D0 (enExample)
WO (1) WO2006056779A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0523954D0 (en) * 2005-11-24 2006-01-04 Ucb Celltech Bioassays
WO2007060411A1 (en) * 2005-11-24 2007-05-31 Ucb Pharma S.A. Anti-tnf alpha antibodies which selectively inhibit tnf alpha signalling through the p55r
MX2008014692A (es) 2006-05-19 2009-08-18 Alder Biopharmaceuticals Inc Metodo de cultivo para obtener una poblacion clonal de celulas b especificas de antigeno.
WO2011026102A1 (en) * 2009-08-31 2011-03-03 Life Technologies Corporation Methods of bead manipulation and forming bead arrays
WO2011095174A1 (en) 2010-02-08 2011-08-11 Aarhus Universitet Human herpes virus 6 and 7 u20 polypeptide and polynucleotides for use as a medicament or diagnosticum
GB201522394D0 (en) * 2015-12-18 2016-02-03 Ucb Biopharma Sprl Antibodies
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2055168A1 (en) 1990-11-21 1992-05-22 Walter Fiers Tnf-muteins
GB9109645D0 (en) 1991-05-03 1991-06-26 Celltech Ltd Recombinant antibodies
SK376492A3 (en) 1992-04-02 1995-06-07 Hoffmann La Roche Tnf - muteins and method of their production
CA2119089A1 (en) 1993-03-29 1994-09-30 David Banner Tumor necrosis factor muteins
US5606023A (en) 1994-05-24 1997-02-25 Thomas Jefferson University Mutant tumor necrosis factor proteins
EP1077723A1 (en) 1998-05-18 2001-02-28 Applied Research Systems ARS Holding N.V. Methods and use of compositions comprising tnf-rii(p75) agonists for treating asthma and other allergic conditions
DE19957065B4 (de) * 1999-11-26 2005-01-05 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Screening-Verfahren für Arzneistoffe
GB0013810D0 (en) 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products
UA81743C2 (uk) * 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
ATE524196T1 (de) * 2001-10-16 2011-09-15 Macrogenics West Inc An das krebsassoziierte antigen cd46 bindende antikörper und verwendungsverfahren dafür
WO2003074679A2 (en) * 2002-03-01 2003-09-12 Xencor Antibody optimization
AU2003225976A1 (en) 2002-03-26 2003-10-13 Centocor, Inc. Anti-tnf antibodies, compositions, methods and uses
JP4754219B2 (ja) * 2002-12-02 2011-08-24 アムジエン・フレモント・インコーポレイテツド 腫瘍壊死因子を対象とする抗体、およびそれらの使用

Similar Documents

Publication Publication Date Title
JP2007511593A5 (enExample)
JP2007051159A5 (enExample)
JP2008538564A5 (enExample)
JP2024075713A5 (enExample)
UY32599A (es) Formulación oral sólida de abt-263
JP2020507587A5 (enExample)
CN115698079A (zh) 抗cd79b抗体药物偶联物、其制备方法及其医药用途
JP2007501251A5 (enExample)
LUC00053I9 (fr) Anticorps diriges contre cd38 pour le traitement du myelome multiple
JP2010500360A5 (enExample)
JP2012121878A5 (enExample)
JP2009511480A5 (enExample)
JP2007514005A5 (enExample)
WO2008064321A3 (en) Methods of treating chronic inflammatory diseases using a gm-csf antagonist
RU2010141584A (ru) Антитело против csf-1r
JP2010529118A5 (enExample)
JP2012021001A5 (enExample)
JP2015534578A5 (enExample)
JP2005516606A5 (enExample)
BRPI0513959A (pt) anticorpos dirigidos contra o peptìdeo beta-amilóide, suas composições farmacêuticas, kit e métodos de fabricação dos mesmos
JP2006514636A5 (enExample)
JP2008521783A5 (enExample)
WO2006093784A3 (en) Dosage forms of antibiotics and combinations of antibiotics ans symptomatic relief agents
JP2007512348A5 (enExample)
WO2006083780A3 (en) Glucuronidated nebivolol